60 related articles for article (PubMed ID: 26420644)
1. How can we improve the translational landscape for a faster cure of type 1 diabetes?
von Herrath M; Chan A
J Clin Invest; 2009 May; 119(5):1061-5. PubMed ID: 19422092
[TBL] [Abstract][Full Text] [Related]
2. Moving research to patient applications through commercialization: understanding and evaluating the role of intellectual property.
Patino RM
J Am Assoc Lab Anim Sci; 2010 Mar; 49(2):147-54. PubMed ID: 20353687
[TBL] [Abstract][Full Text] [Related]
3. Academic drug discovery: Challenges and opportunities.
Murray AJ; Cox LR; Adcock HV; Roberts RA
Drug Discov Today; 2024 Apr; 29(4):103918. PubMed ID: 38360148
[TBL] [Abstract][Full Text] [Related]
4. Open access target validation is a more efficient way to accelerate drug discovery.
Lee WH
PLoS Biol; 2015 Jun; 13(6):e1002164. PubMed ID: 26042736
[TBL] [Abstract][Full Text] [Related]
5. Intellectual property in medical imaging and informatics: the independent inventor's perspective.
Reiner BI
J Digit Imaging; 2008 Mar; 21(1):3-8. PubMed ID: 18175182
[TBL] [Abstract][Full Text] [Related]
6. The fate of drug discovery in academia; dumping in the publication landfill?
Saqib U; Demaree IS; Obukhov AG; Baig MS; Ariel A; Hajela K
Oncotarget; 2024 Jan; 15():31-34. PubMed ID: 38275290
[No Abstract] [Full Text] [Related]
7. Drug Discovery in Academia- the third way?
Frearson J; Wyatt P
Expert Opin Drug Discov; 2010 Oct; 5(10):909-19. PubMed ID: 20922062
[TBL] [Abstract][Full Text] [Related]
8. Medicines for millions of patients.
Rees DC
RSC Med Chem; 2022 Jan; 13(1):7-12. PubMed ID: 35211673
[TBL] [Abstract][Full Text] [Related]
9. The innovation menagerie: New institutional structures are expanding horizons for early-stage research.
Rodriques SG
Cell; 2024 Jan; 187(1):3-7. PubMed ID: 38181742
[TBL] [Abstract][Full Text] [Related]
10. Challenging the high-dose paradigm for cancer drugs.
Banks MA
Nature; 2022 Dec; ():. PubMed ID: 36517682
[No Abstract] [Full Text] [Related]
11. Value added medicines: what value repurposed medicines might bring to society?
Toumi M; Rémuzat C
J Mark Access Health Policy; 2017; 5(1):1264717. PubMed ID: 28265347
[No Abstract] [Full Text] [Related]
12. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
13. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
Palmer M; Chaguturu R
Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
[No Abstract] [Full Text] [Related]
14. Public-private relationships in biobanking: a still underestimated key component of open innovation.
Hofman P; Bréchot C; Zatloukal K; Dagher G; Clément B
Virchows Arch; 2014 Jan; 464(1):3-9. PubMed ID: 24337181
[TBL] [Abstract][Full Text] [Related]
15. [Challenges and strategies of drug innovation].
Guo ZR; Zhao HY
Yao Xue Xue Bao; 2013 Jul; 48(7):1031-40. PubMed ID: 24133969
[TBL] [Abstract][Full Text] [Related]
16. Professional translational research: a new hybrid paradigm in early drug discovery.
Nussbaumer P; Klebl B
Future Med Chem; 2015; 7(14):1879-89. PubMed ID: 26420644
[TBL] [Abstract][Full Text] [Related]
17. Narrowing the translational research gap: what needs to be done?
Wolkowicz R
Future Med Chem; 2015; 7(14):1843-6. PubMed ID: 26393393
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
